X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs DR. REDDYS LAB - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH DR. REDDYS LAB PANACEA BIOTECH/
DR. REDDYS LAB
 
P/E (TTM) x 84.6 27.3 310.4% View Chart
P/BV x 1.9 2.8 66.9% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 PANACEA BIOTECH   DR. REDDYS LAB
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
DR. REDDYS LAB
Mar-16
PANACEA BIOTECH/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1494,383 3.4%   
Low Rs822,750 3.0%   
Sales per share (Unadj.) Rs84.1920.1 9.1%  
Earnings per share (Unadj.) Rs-18.3126.1 -14.5%  
Cash flow per share (Unadj.) Rs-6.7183.0 -3.7%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs83.7685.8 12.2%  
Shares outstanding (eoy) m61.25170.61 35.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.43.9 35.4%   
Avg P/E ratio x-6.328.3 -22.3%  
P/CF ratio (eoy) x-17.219.5 -88.5%  
Price / Book Value ratio x1.45.2 26.5%  
Dividend payout %015.9 0.0%   
Avg Mkt Cap Rs m7,074608,481 1.2%   
No. of employees `0002.821.7 12.7%   
Total wages/salary Rs m1,44931,874 4.5%   
Avg. sales/employee Rs Th1,874.17,244.4 25.9%   
Avg. wages/employee Rs Th527.01,470.9 35.8%   
Avg. net profit/employee Rs Th-407.7992.8 -41.1%   
INCOME DATA
Net Sales Rs m5,154156,978 3.3%  
Other income Rs m1002,693 3.7%   
Total revenues Rs m5,254159,671 3.3%   
Gross profit Rs m-76634,587 -2.2%  
Depreciation Rs m7119,705 7.3%   
Interest Rs m1,503824 182.4%   
Profit before tax Rs m-2,88126,751 -10.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m175,237 0.3%   
Profit after tax Rs m-1,12121,514 -5.2%  
Gross profit margin %-14.922.0 -67.5%  
Effective tax rate %-0.619.6 -3.0%   
Net profit margin %-21.813.7 -158.8%  
BALANCE SHEET DATA
Current assets Rs m3,810118,201 3.2%   
Current liabilities Rs m8,36568,368 12.2%   
Net working cap to sales %-88.431.7 -278.4%  
Current ratio x0.51.7 26.3%  
Inventory Days Days15660 259.5%  
Debtors Days Days6797 69.4%  
Net fixed assets Rs m14,48072,265 20.0%   
Share capital Rs m61853 7.2%   
"Free" reserves Rs m903111,548 0.8%   
Net worth Rs m5,127117,009 4.4%   
Long term debt Rs m5,83210,690 54.6%   
Total assets Rs m19,433200,104 9.7%  
Interest coverage x-0.933.5 -2.7%   
Debt to equity ratio x1.10.1 1,245.0%  
Sales to assets ratio x0.30.8 33.8%   
Return on assets %2.011.2 17.6%  
Return on equity %-21.918.4 -118.9%  
Return on capital %3.621.6 16.8%  
Exports to sales %24.546.3 53.0%   
Imports to sales %10.29.0 113.8%   
Exports (fob) Rs m1,26472,618 1.7%   
Imports (cif) Rs m52514,050 3.7%   
Fx inflow Rs m1,53975,405 2.0%   
Fx outflow Rs m94227,115 3.5%   
Net fx Rs m59748,290 1.2%   
CASH FLOW
From Operations Rs m59940,476 1.5%  
From Investments Rs m-438-19,421 2.3%  
From Financial Activity Rs m-303-17,009 1.8%  
Net Cashflow Rs m-1414,046 -3.5%  

Share Holding

Indian Promoters % 74.5 25.5 292.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 5.4 11.1%  
FIIs % 1.3 35.3 3.7%  
ADR/GDR % 0.0 18.5 -  
Free float % 23.6 15.3 154.2%  
Shareholders   10,259 75,885 13.5%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 18, 2017 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - CIPLA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS